Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
Targeting Sodium Channels as a Novel Approach to Preventing Type 1 Diabetes
FY 2024-25
Summary
Type 1 diabetes is an autoimmune disease where the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Without sufficient insulin, blood glucose levels can rise to dangerous levels. As a result, people with type 1 diabetes rely on lifelong artificial insulin to manage their blood glucose and avoid serious health complications. There are no treatments to permanently stop the progression of type 1 diabetes. To address this, our research group is exploring a promising new approach: protecting beta cells by targeting ion channels. Ion channels act like gates on the surface of beta cells, regulating the electrical activity essential for insulin secretion. However, in type 1 diabetes, immune signals overstimulate these ion channels, causing beta cells to become overactive and die. Our team has identified carbamazepine, a drug already approved by the US Food & Drug Administration to treat epilepsy, as a potential solution. After screening numerous drugs, we found that carbamazepine protects isolated beta cells from the immune attack in type 1 diabetes. We also showed that carbamazepine treatment reduced the development of type 1 diabetes by 50% in mice that spontaneously get the disease. Recently, we confirmed that carbamazepine works by inhibiting a specific sodium channel, encoded by the Scn9a gene. These exciting findings open a new avenue for drug development in type 1 diabetes. We will build on these discoveries by exploring exactly how the Scn9a sodium channel helps protect beta cells, strengthening its role as a therapeutic target. We will also test other Scn9a sodium channel inhibiting drugs as potentially more efficient alternatives to carbamazepine. This work aims to establish a groundbreaking strategy for type 1 diabetes prevention.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530090
Name
Gordon Abby G
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Sodium Channels as a Novel Approach to Preventing Type 1 Diabetes
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Beta Cell Survival; Beta Cells; Carbamazepine; Drug Screening; Excitotoxicity; Ion Channels; Preventative Medicine; Scn9a Sodium Channel; Sodium Channel Blockers; Type 1 Diabetes
Abstract
Type 1 diabetes is an autoimmune disease where the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Without sufficient insulin, blood glucose levels can rise to dangerous levels. As a result, people with type 1 diabetes rely on lifelong artificial insulin to manage their blood glucose and avoid serious health complications. There are no treatments to permanently stop the progression of type 1 diabetes. To address this, our research group is exploring a promising new approach: protecting beta cells by targeting ion channels. Ion channels act like gates on the surface of beta cells, regulating the electrical activity essential for insulin secretion. However, in type 1 diabetes, immune signals overstimulate these ion channels, causing beta cells to become overactive and die. Our team has identified carbamazepine, a drug already approved by the US Food & Drug Administration to treat epilepsy, as a potential solution. After screening numerous drugs, we found that carbamazepine protects isolated beta cells from the immune attack in type 1 diabetes. We also showed that carbamazepine treatment reduced the development of type 1 diabetes by 50% in mice that spontaneously get the disease. Recently, we confirmed that carbamazepine works by inhibiting a specific sodium channel, encoded by the Scn9a gene. These exciting findings open a new avenue for drug development in type 1 diabetes. We will build on these discoveries by exploring exactly how the Scn9a sodium channel helps protect beta cells, strengthening its role as a therapeutic target. We will also test other Scn9a sodium channel inhibiting drugs as potentially more efficient alternatives to carbamazepine. This work aims to establish a groundbreaking strategy for type 1 diabetes prevention.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gordon, Abby G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~